Israeli Technology to Help Breast-Cancer Patients

June 26, 2005

The technology, developed by Optimata Ltd., creates an “in silico“ clone for each patient, which can predict how the patient will respond to leading cancer drugs, such as Adriamycin, Docetaxel, Paclitaxel, Vinorelbine, and Tamoxifen.The goal is to improve the effectiveness of current breast-cancer treatments and to avoid the harsh and toxic treatments that patients must undergo. At present, a patient’s schedule of chemotherapy treatment is based on trial and error.

“Breast-cancer patients currently are all treated according to the same chemotherapy protocols,” said Professor Samuel Ariad, head of Soroka’s Institute of Oncology, “yet only between 15% to 65% of the patients respond to the chemotherapy. There is a need to find an empirical way of individualizing the therapy for each patient.”

Upon completion of the research, Optimata plans to use the Virtual Cancer Patient technology to provide clinical trials in order to recommend optimal dosing and scheduling regimens for actual breast-cancer patients on an individual basis.

For further information, please contact Optimata Ltd., 11 Tuval Street, Ramat Gan 52522, Israel; Tel: 972-3-751-9226; FAX: 972-3-751-9229; E-mail: [email protected]; Web site: www.optimata.com

Photo Credit: